JONATHAN FLANAGAN

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Faculty Mentor
    Collapse Verify Publications

    Collapse Overview 
    Collapse overview
    The long term goal of my research is to identify genetic variants that affect the clinical severity of patients with sickle cell anemia (SCA). SCA is a common disorder caused by a single mutation of the beta-globin gene but the individual severity of clinical outcome is highly variable. It is increasingly apparent that some of this variability is due to co-inheritance of genetic variants other than the SCA mutation. I have a comprehensive background in the study of genetics and completed my postdoctoral training in the field of hematology. This has allowed me to complete several translational projects involving genetics and hematology. During my postdoctoral fellowships at The Scripps Research Institute and St. Jude Children’s Research Hospital, I carried out research projects that investigated the molecular mechanisms of iron overload and the genetic modifiers that affected patient response to the drug hydroxyurea. My laboratory is now working on identifying novel genetic variants that are associated with disease severity of SCA and using state-of-the art molecular biology techniques to decipher the molecular pathways that are involved.

    Collapse Research 
    Collapse research activities and funding
    R21HL123641     (FLANAGAN, JONATHAN MICHAEL)Aug 1, 2015 - Jul 31, 2017
    NIH/NHLBI
    Genetic Modifiers of Transfusional Iron Overload
    Role: Principal Investigator

    R56HL136415     (FLANAGAN, JONATHAN MICHAEL)Sep 25, 2017 - Aug 31, 2018
    NIH/NHLBI
    NOVEL PATHWAYS IN ISCHEMIC STROKE IN SICKLE CELL ANEMIA
    Role: Principal Investigator

    R01HL136415     (FLANAGAN, JONATHAN MICHAEL)Aug 1, 2019 - Jun 30, 2022
    NIH/NHLBI
    Novel Pathways in Ischemic Stroke in Sickle Cell Anemia
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chang TC, Haupfear KM, Yu J, Rampersaud E, Sheehan VA, Flanagan JM, Hankins JS, Weiss MJ, Wu G, Vege S, Westhoff CM, Chou ST, Zheng Y. A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data. Blood Adv. 2020 Sep 22; 4(18):4347-4357. PMID: 32915977.
      Citations:    Fields:    
    2. Kim TO, Flanagan JM, Habibi A, Arulselvan A, Lambert MP, Grace RF, Despotovic JM. Genetic variants in toll-like receptor 4 are associated with lack of steroid-responsiveness in pediatric ITP patients. Am J Hematol. 2020 Jan 05. PMID: 31903617.
      Citations:    Fields:    
    3. Puri L, Flanagan JM, Kang G, Ding J, Bi W, McCarville BM, Loeffler RB, Tipirneni-Sajja A, Villavicencio M, Crews KR, Hillenbrand CM, Hankins JS. GSTM1 and Liver Iron Content in Children with Sickle Cell Anemia and Iron Overload. J Clin Med. 2019 Nov 05; 8(11). PMID: 31694285.
      Citations:    
    4. Mathur T, Singh KA, R Pandian NK, Tsai SH, Hein TW, Gaharwar AK, Flanagan JM, Jain A. Organ-on-chips made of blood: endothelial progenitor cells from blood reconstitute vascular thromboinflammation in vessel-chips. Lab Chip. 2019 07 23; 19(15):2500-2511. PMID: 31246211.
      Citations: 5     Fields:    Translation:HumansCells
    5. Amlie-Lefond C, Flanagan J, Kanter J, Dobyns WB. The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia. J Stroke Cerebrovasc Dis. 2018 Nov; 27(11):2897-2904. PMID: 30076115.
      Citations: 1     Fields:    Translation:HumansAnimals
    6. Mwesigwa S, Moulds JM, Chen A, Flanagan J, Sheehan VA, George A, Hanchard NA. Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition. Transfusion. 2018 03; 58(3):726-735. PMID: 29210071.
      Citations: 1     Fields:    Translation:Humans
    7. Chou ST, Flanagan JM, Vege S, Luban NLC, Brown RC, Ware RE, Westhoff CM. Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Adv. 2017 Aug 08; 1(18):1414-1422. PMID: 29296782.
      Citations: 12     Fields:    
    8. Friedrisch JR, Sheehan V, Flanagan JM, Baldan A, Summarell CC, Bittar CM, Friedrisch BK, Wilke II, Ribeiro CB, Daudt LE, da Rocha Silla LM. The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil. Blood Cells Mol Dis. 2016 11; 62:32-37. PMID: 27838552.
      Citations: 3     Fields:    Translation:Humans
    9. Schaefer BA, Flanagan JM, Alvarez OA, Nelson SC, Aygun B, Nottage KA, George A, Roberts CW, Piccone CM, Howard TA, Davis BR, Ware RE. Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. PLoS One. 2016; 11(10):e0164364. PMID: 27711207.
      Citations: 5     Fields:    Translation:HumansCells
    10. Sheehan VA, Crosby JR, Sabo A, Mortier NA, Howard TA, Muzny DM, Dugan-Perez S, Aygun B, Nottage KA, Boerwinkle E, Gibbs RA, Ware RE, Flanagan JM. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia. PLoS One. 2014; 9(10):e110740. PMID: 25360671.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    11. Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013 Nov; 88(11):932-8. PMID: 23861242.
      Citations: 13     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    12. Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol. 2013 Jul; 88(7):571-6. PMID: 23606168.
      Citations: 23     Fields:    Translation:HumansCells
    13. Flanagan JM, Sheehan V, Linder H, Howard TA, Wang YD, Hoppe CC, Aygun B, Adams RJ, Neale GA, Ware RE. Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood. 2013 Apr 18; 121(16):3237-45. PMID: 23422753.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    14. Flanagan JM, Steward S, Howard TA, Mortier NA, Kimble AC, Aygun B, Hankins JS, Neale GA, Ware RE. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol. 2012 Apr; 157(2):240-8. PMID: 22360576.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    15. McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya AS, Thompson BW, Ware RE. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer. 2012 Aug; 59(2):254-7. PMID: 22012708.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    16. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 03; 118(18):4985-91. PMID: 21876119.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    17. Miller ST, Rey K, He J, Flanagan J, Fish BJ, Rogers ZR, Wang WC, Ware RE. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatr Blood Cancer. 2012 Jul 15; 59(1):170-2. PMID: 21744485.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    18. McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011 Jul; 154(1):134-40. PMID: 21542824.
      Citations: 10     Fields:    Translation:HumansCells
    19. Flanagan JM, Frohlich DM, Howard TA, Schultz WH, Driscoll C, Nagasubramanian R, Mortier NA, Kimble AC, Aygun B, Adams RJ, Helms RW, Ware RE. Genetic predictors for stroke in children with sickle cell anemia. Blood. 2011 Jun 16; 117(24):6681-4. PMID: 21515823.
      Citations: 37     Fields:    Translation:Humans
    20. Flanagan JM, Howard TA, Mortier N, Avlasevich SL, Smeltzer MP, Wu S, Dertinger SD, Ware RE. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res. 2010 Apr 30; 698(1-2):38-42. PMID: 20230905.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    21. Bouchier-Hayes L, Oberst A, McStay GP, Connell S, Tait SW, Dillon CP, Flanagan JM, Beere HM, Green DR. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell. 2009 Sep 24; 35(6):830-40. PMID: 19782032.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    22. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Am J Hematol. 2009 Jun; 84(6):328-34. PMID: 19384939.
      Citations: 3     Fields:    Translation:Humans
    23. Truksa J, Lee P, Peng H, Flanagan J, Beutler E. The distal location of the iron responsive region of the hepcidin promoter. Blood. 2007 Nov 01; 110(9):3436-7. PMID: 17644736.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    24. Flanagan JM, Truksa J, Peng H, Lee P, Beutler E. In vivo imaging of hepcidin promoter stimulation by iron and inflammation. Blood Cells Mol Dis. 2007 May-Jun; 38(3):253-7. PMID: 17331760.
      Citations: 7     Fields:    Translation:AnimalsCells
    25. Flanagan JM, Peng H, Beutler E. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcohol Clin Exp Res. 2007 Jan; 31(1):138-43. PMID: 17207112.
      Citations: 11     Fields:    Translation:Animals
    26. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet. 2006 Nov; 120(4):581-8. PMID: 16972078.
      Citations: 33     Fields:    Translation:HumansCells
    27. Flanagan JM, Rhodes M, Wilson M, Beutler E. The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol. 2006 Jul; 134(2):233-7. PMID: 16740138.
      Citations: 8     Fields:    Translation:Humans
    28. Flanagan JM, Beutler E. The genetic basis of human erythrocyte pyridoxal kinase activity variation. Haematologica. 2006 Jun; 91(6):801-4. PMID: 16704963.
      Citations: 2     Fields:    Translation:HumansCells
    29. Noel N, Flanagan JM, Flanagan J, Ramirez Bajo MJ, Kalko SG, Mañú Mdel M, Garcia Fuster JL, Perez de la Ossa P, Carreras J, Beutler E, Vives Corrons JL. Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol. 2006 Feb; 132(4):523-9. PMID: 16412025.
      Citations: 8     Fields:    Translation:HumansCells
    30. Flanagan JM, Peng H, Wang L, Gelbart T, Lee P, Johnson Sasu B, Beutler E. Soluble transferrin receptor-1 levels in mice do not affect iron absorption. Acta Haematol. 2006; 116(4):249-54. PMID: 17119325.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    31. Tighe O, Flanagan JM, Kernan F, O'Neill C, Naughten E, Mayne PD, Croke DT. Frequency distribution of the Los Angeles and Duarte galactose-1-phosphate uridyltransferase variant alleles in the Irish population. Mol Genet Metab. 2004 Aug; 82(4):345-7. PMID: 15308134.
      Citations: 2     Fields:    Translation:Humans
    32. Flanagan JM, Tighe O, O' Neill C, Naughten E, Mayne PD, Croke DT. Identification of sequence variation in the galactose-1-phosphate uridyl transferase gene by dHPLC. Mol Genet Metab. 2004 Feb; 81(2):133-6. PMID: 14741195.
      Citations: 1     Fields:    Translation:HumansCells
    FLANAGAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (204)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _